|
|
|
《英特华观察》是我们交流对在华业务的投资、市场与实用主题方面看法的平台。下面列出当前的和以往存档的文章。欢迎下载和打印，以便您在空闲时阅读。
Current Edition
|
 |
|
| |
InterChina presents recent developments in industry consolidation in China, acquisition strategies, and shares experiences in our key transaction executions. |
| |
Barry Chen |
PDF | EN | 2018-03-15 |
| |
|
| |
In some case, the “Xi Jinping Thought” will be favorable for foreign companies, in others not… Nevertheless, clarity will help to build confidence and drive decisions. |
| |
Jan Borgonjon, Eduardo Morcillo, James Sinclair, Simon Zhang, Barry Chen, Franc Kaiser |
PDF | EN | 2017-12-07 |
| |
|
| |
As we head into 2018, we expect a more positive business environment for foreign companies operating in China. The onus is now on the foreign companies to take advantage. For some, that will mean exploiting advantages they have over local competitors in product technologies and performance. Others will focus on seeking out acquisitions as their sectors consolidate. For most, they will need to further organize themselves to better respond to local market needs. |
| |
Jan Borgonjon, Eduardo Morcillo, James Sinclair, Simon Zhang, Barry Chen, Franc Kaiser |
PDF | EN | 2017-12-07 |
| |
|
| |
France's Faurecia announced on 19th July, 2017 that it had taken a majority share in Chinese company Jiangxi Coagent Electronics for a total investment of 1.45 billion RMB.
|
| |
Eduardo Morcillo, Raymond Su |
PDF | EN | 2017-07-25 |
| |
|
| |
After changing its strategy to focus on branded products instead of B2B businesses, Tata Global Beverages engaged InterChina to divest its equity (90%) holdings in Zhejiang Tata Tea Extraction Company Ltd.(“ZTTECL”). ZTTECL manufactures and markets tea extraction products in two target segments: instant tea (used in ready-to-drink tea-based beverages) and tea polyphenols (for use in food supplements, ready-to-drink beverages, cosmetics, etc.). Zhejiang Tea has entered an agreement to purchase, subject to regulatory approval. |
| |
Barry Chen |
PDF | EN | 2017-07-19 |
| |
|
| |
InterChina co-authored a new report on the Chinese medtech sector together with Dr. Urs Mattes from Swiss Global Enterprise. The report provides an excellent and to-the-point assessment of where the Chinese medtech market, competition and regulatory framework currently stands, and has received high praise from Swiss medtech companies active in China. InterChina’s contribution is focusing on dusting off the myths of China’s M&A medtech sector, and features a clear overview of inbound, outbound, and domestic M&A deals. Foreign players have refrained from inbound M&A activities after the large acquisitions of Medtronic and Stryker. The domestic M&A market, however, remains active, particularly driven by IVD. China’s medtech outbound investments have been directed towards innovation and technology that is superior to those of the buyer and for which China will have a future market to offer. |
| |
Dr. Urs Mattes, Franc Kaiser, Richard Beswick, Jens Haarmann |
PDF | EN | 2017-06-29 |
|
|
|
|
战略咨询
|
|
英特华帮助客户解决在中国市场及国际市场的各种问题和挑战.
|
|
|
|
行业
|
|
英特华在一些重要行业方面侧重发展了自己的知识专长，从而有能力为客户提供富有创见、切实可行的解决方案。英特华公司专注于我们主要行业的深度研究，为我们的客户提供前瞻性和务实的解决方案。
|
|
|
|
职位招聘
|
|
我们一直致力于搜寻最顶尖的人才，同时欢迎不同级别的新人加入我们的团队
|
|
|
| |
|
